The current generation of total ankle replacements, uncemented and avoiding rotational strain in a 3-component design with a polyethylene meniscus, have shown promising but varying results in medium-term and long-term reports ([@CIT0015], [@CIT0005], [@CIT0006], [@CIT0023], [@CIT0025], [@CIT0004], [@CIT0014]). National registries have a large number of patients operated on by different surgeons, and may thus give better insight into the current situation than what can be reported from a single surgeon or institution. 5-year prosthetic survival rates of between 0.78 and 0.88 have been reported by the Norwegian, Swedish, New Zealand, and Finnish national registries. ([@CIT0007], [@CIT0009], [@CIT0013], [@CIT0019]). Here we present longer-term follow-up of total arthroplasties reported to the Swedish Ankle Register.

Patients and methods {#ss2}
====================

The first of the third-generation total ankle replacements in Sweden were performed in 1993. Since then, all total ankle replacements are reported to a national register by each surgeon using a paper form. Hospital data, demographic data, date of index operation, date of revision surgery, operated side, diagnosis (primary or reason for revision), type of prosthesis, and---in cases of revision---the type of procedure are reported.

Between April 14, 1993, and June 15, 2010, 780 primary total ankle replacements were reported to the register ([Table 1](#T1){ref-type="table"}). Because of small numbers of the BP, AES, Mobility, and CCI prostheses---and due the similarity in design---these implants were analyzed together as a group called BP-type. The diagnoses were rheumatoid arthritis (RA) in 282 cases (36%), primary or idiopathic osteoarthritis (OA) in 185 (24%), posttraumatic arthritis (PtA) in 266 (34%), and various diagnoses including hemophilia, hemochromatosis, and psoriatic arthritis in 47 cases (6%) ([Table 2](#T2){ref-type="table"}). 31 patients with RA and 23 patients with other diagnoses had both ankles replaced.

###### 

Numbers of ankle prostheses implanted in Sweden annually

  Year                                    STAR   BP    AES   Hintegra   Mobility   CCI   Total
  --------------------------------------- ------ ----- ----- ---------- ---------- ----- -------
  1993                                    6                                              6
  1994                                    13                                             13
  1995                                    11                                             11
  1996                                    8                                              8
  1997                                    24                                             24
  1998                                    34                                             34
  1999                                    25                                             25
  2000                                    45     1                                       46
  2001                                    48                                             48
  2002                                    40     21    3     10                          74
  2003                                    25     23    17    14                          79
  2004                                    17     29    16    4                           66
  2005                                    18     13    23    2          9                65
  2006                                    7      11    21    6          21               66
  2007                                    1      7     18               20               46
  2008                                           4     17               32         16    69
  2009                                                                  31         40    71
  2010 **[^a^](#T1-N1){ref-type="fn"}**                                 19         10    29
  Total                                   322    109   115   36         136        66    780

**^a^** up to June 15

###### 

Demographic data

                                         n     \% females   Mean age (range)
  -------------------------------------- ----- ------------ ------------------
  RA                                     282   78           56 (18--86)
  OA                                     185   48           62 (30--84)
  PtA **[^a^](#T2-N1){ref-type="fn"}**   266   54           58 (25--86)
  Other                                  47    47           56 (28--74)
  All diagnoses                          780   61           58 (18--86)

**^a^** posttrauma arthritis.

Statistics {#ss3}
----------

Survival curves were constructed according to Kaplan-Meier. Cox proportional regression was used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs). The assumptions for Cox regression analysis were evaluated graphically in survival curves and log-minus-log plots and were estimated to be fullfilled. As endpoint, we used revision leading to exchange or extraction of 1 or more of the 3 prosthetic components with the exception of incidental exchange of the polyethylene insert ([@CIT0012]). 3 patients were revised bilaterally, and both ankles were included in the analyses. Inclusion of bilateral observations in arthroplasty studies appears to have a negligible effect on survival estimates ([@CIT0018]).

Results {#ss4}
=======

17 hospitals had reported to the Swedish Ankle Register, but at the time of writing total ankle replacement is only performed at 6 hospitals in Sweden.

168 ankles (22%) were revised ([Table 3](#T3){ref-type="table"}). 67 (40%) of them were revised because of loosening of the tibial and/or the talar component, and another 21 because of instability with or without dislocation of the polyethylene (PE) meniscus. 19 ankles were considered to be technical failures by the surgeons performing the revisions, with malpositioning of the tibial component---too lateral or too medial, or at an incorrect angle. Use of a tibial component that was too short from front to back was also considered to be a technical error. Severe pain for no obvious reason in 11 ankles eventually resulted in revision. In addition, 17 ankles were revised because of severe wear or fracture of the mobile bearing component.

###### 

Reasons for revision

                          Single-coated   Double-coated                               
  ----------------------- --------------- --------------- ----- ----- ---- ----- ---- -----
  Numbers                 117             205             109   115   36   132   66   780
  Aseptic loosening       33              16              4     5     3    2     4    67
  Technical error         8               8                     1     2               19
  Instability             1               2               5     8     1    3     1    21
  Infection               3               10              1     2     1    2          19
  Intractable pain        4               6                                1          11
  PE breakdown/fracture   7               4               3     1          2          17
  Painful varus                           2               1     4     1          1    9
  Fracture                                1               3     1                     5
  Total                   56              49              17    22    8    10    6    168

30 cases (4%) were complicated by septic arthritis. 19 of those required revision and were included when we calculated prosthetic survival. The remaining cases were treated with antibiotics, synovectomy, and washout.

The revison rate was 21--22% both in the unilateral and the bilateral ankles. There were 118 other secondary procedures that were not classified as revisions e.g. subtalar, triple, or talo-navicular fusions, debridement of the medial gutter, deltoid ligament release, and Achilles tendon lengthening.

The estimated overall 5-year survival rate was 0.81 (CI: 0.79--0.83) and the 10-year survival rate was 0.69 (CI: 0.67--0.71) ([Figure 1](#F1){ref-type="fig"} and [Table 4](#T4){ref-type="table"}). For RA patients, the estimated survival rate at 10 years was 0.72, for OA patients it was 0.68, and for patients with posttraumatic arthritis it was 0.66 ([Figure 2](#F2){ref-type="fig"}). Compared to OA patients, HR for RA patients was 0.9 (CI: 0.6--1.3) and compared to patients with posttraumatic arthritis it was 0.7 (CI: 0.5--1.0). No statistically significant difference was found between the BP-type prostheses (BP, AES, Mobility, and CCI (p = 0.24). The 10-year survival rate of the single-coated STAR was 0.58 ([Figure 3](#F3){ref-type="fig"}). The prosthetic survival rate was statistically significantly lower for the single-coated STAR prostheses implanted between 1993 and 1999 than for the BP-type prostheses (HR = 1.7; CI: 1.1--9.5). The survival rates of the Hintegra and double-coated STAR prostheses were similar to that of the BP-type prostheses ([Table 5](#T5){ref-type="table"}).

![Estimated cumulative survival and 95% CI for all 780 arthroplasties.](ORT-0300-9734-082-655_g001){#F1}

###### 

Life table

  Interval (years)   No. entering the interval   No. of events   Cumulative proportion surviving at the end of the interval   95% CI
  ------------------ --------------------------- --------------- ------------------------------------------------------------ ------------
  0--1               780                         46              0.94                                                         0.93--0.95
  1--2               674                         33              0.89                                                         0.88--0.90
  2--3               568                         17              0.86                                                         0.85--0.87
  3--4               496                         15              0.83                                                         0.82--0.84
  4--5               434                         14              0.81                                                         0.79--0.83
  5--6               355                         13              0.77                                                         0.75--0.79
  6--7               288                         8               0.75                                                         0.73--0.77
  7--8               219                         5               0.73                                                         0.71--0.75
  8--9               165                         5               0.70                                                         0.68--0.72
  9--10              114                         2               0.69                                                         0.67--0.71

![Estimated cumulative survival for ankles replaced due to rheumatoid arthritis (purple), osteoarthritis (red), and posttraumatic osteoarthritis (green).](ORT-0300-9734-082-655_g002){#F2}

![Estimated survival for the different designs implanted. The blue curve represents the BP-type designs, the green curve the Hintegra, the purple curve the double-coated STAR, and the red curve the single-coated STAR prostheses.](ORT-0300-9734-082-655_g003){#F3}

###### 

Hazard ratio (HR) of survival rates for different prostheses

  Prosthesis                HR    95% CI
  ------------------------- ----- -----------
  BP-type                   1     Reference
  Hintegra                  1.2   0.57--2.5
  STAR I (single-coated)    1.7   1.1--2.5
  STAR II (double-coated)   1.1   0.75--1.6

Patients younger than 60 years of age with OA or posttraumatic arthritis had a statistically significantly higher risk of revision than patients who were older than 60 years (HR = 1.8; CI: 1.3--2.8). This risk was statistically significant for women (HR = 2.0; CI: 1.2--3.6) but not for men. Age had no influence on the revision rate in patients with RA (HR = 1.4; CI: 0.8--2.4). Revisions due to technical error, infection, and instability were undertaken earlier than those undertaken as a result of component loosening and meniscal wear ([Table 6](#T6){ref-type="table"}).

###### 

Time (years) and 95% CI from index surgery to revision

  Reason for revision         Mean   95% CI
  --------------------------- ------ ----------
  Valgus malalignment         1.0    0.2--1.8
  Infection                   1.2    0.6--1.8
  Technical error             1.3    0.6--2.0
  Fracture                    1.4    0.3--3.0
  Instability                 1.8    0.9--2.7
  Loosening tibia             2.5    1.7--3.3
  Intractable pain            2.5    1.6--3.4
  Varus malalignment          2.9    1.3--4.4
  Loosening talus and tibia   5.3    4.0--6.5
  PE breakdown/fracture       5.6    3.8--7.5
  Loosening talus             7.8    6.3--9.2

Discussion {#ss5}
==========

The annual number of ankle replacements performed in Sweden (with 9 million inhabitants) increased until 2002, and then a steady state of around 70 per year was reached ([Table 1](#T1){ref-type="table"}). This indicates 1 replacement per 100,000 inhabitants over the age of 15. The corresponding figure is the same in Norway (<http://nrlweb.ihelse.net>) and Scotland ([www.arthro.scot.nhs.uk](www.arthro.scot.nhs.uk)) but twice as many replacements are performed annually in Finland ([@CIT0019]) and 3 times as many are performed in New Zealand ([www.cdhb.govt.nz](www.cdhb.govt.nz)). In Denmark, the corresponding figure is 2.8 ([www.sst.dk](www.sst.dk)) and in England and Wales it is 1.2 ([www.njrcentre.org.uk](www.njrcentre.org.uk)).

Earlier reports from 4 national registries have shown a 5-year survival rate of 78--88% ([@CIT0009], [@CIT0007], [@CIT0013], [@CIT0019]). However, the definitions of a revision of a total ankle replacement were not identical in these reports. Here, for the first time, we present data from a national register for up to 18 years of follow-up of third-generation total ankle replacements. In our first report ([@CIT0009]) we found a survival rate of 78% (95% CI: 74--82) at 5 years for the total material. The endpoint for the calculations was exchange or removal of any of the components ([@CIT0012]).

In the present study, the overall 10-year survival (with identical endpoint) was estimated to be 69% (CI: 67--71). When we excluded the single- and double-coated STAR prostheses (for reasons given below), the 10-year survival was estimated to be 0.78 (CI: 0.72--0.83).

As a rule, specialized units report higher survival rates. Thus, [@CIT0023] found a 10-year survival rate of 0.80 (CI: 0.71--0.90) for 200 STAR prostheses. In smaller material, [@CIT0006] found a 10-year survival rate of 0.89 (CI: 0.82--97) for 74 BP prostheses and [@CIT0014] found an 8-year survival rate of 0.84 (CI: 0.67--0.92) for 52 STAR prostheses. [@CIT0004] reported a 10-year survival rate of 0.85 (CI: 0.75--0.95) for 98 Salto prostheses.

In Sweden, units that were not satisfied with the results after having performed a limited number of replacements decided to perform arthrodeses only and referred candidates for replacement to specialized units. This may have contributed to better results in later years.

We found a statistically significant difference in performance of the single-coated STAR prosthesis compared with the other designs. It performed worse. The only published randomized study comparing different designs of total ankle replacements found better performance of the STAR prosthesis than of the BP prosthesis, but the difference was not statistically significant. That study included both single-coated and double-coated STAR prostheses ([@CIT0024]). Also, 2 systematic reviews of the outcome of total ankle replacements have been published. [@CIT0020] found the weighted 5-year survival of 1,107 third-generation total ankle replacements to be 0.91 (CI: 0.84--0.97). No significant differences between the prostheses included (STAR, ESKA, Ramses, LCS, and BP) were found. [@CIT0008] reported an overall revision rate of 10% for 801 third-generation total ankle replacements (STAR, BP, HINTEGRA, Salto, and Mobility) and no superiority of any of the prostheses after a follow-up of 5 years.

Aseptic loosening of components was the most common reason for revision, and it was mainly a problem with the STAR prosthesis ([Table 3](#T3){ref-type="table"}). The STAR prosthesis was the first third-generation design to be introduced in Sweden, and most surgeons were therefore in a learning phase. Also, the STAR prosthesis is technically demanding and the instrumentation was inferior, at least during the first years. The STAR prosthesis is no longer used in Sweden ([Table 1](#T1){ref-type="table"}). The single-coated STAR is not manufactured any more.

As expected, technical mistakes at surgery, infections, and instability problems resulted in early revision. Meniscal wear and aseptic loosening, notably of the talar component, resulted in later revision. The reason may be that loosening of the tibial component can be seen more easily in radiographs than loosening of the talar component.

In the present study, the risk of revision was increased for patients younger than 60 years with primary osteoarthritis or posttraumatic osteoarthritis. This difference was only statistically significant for women. The revision rate in patients with rheumatoid arthritis was not influenced by age. The revision rate in younger patients was also elevated in our earlier report from the Swedish Ankle Register ([@CIT0009]), but not in the reports from the Norwegian, New Zealand, or Finnish registers ([@CIT0007], [@CIT0013], [@CIT0019]). Younger patients have higher demands and a higher activity level than older patients, which might affect the longevity of a total ankle replacement.

The infection rate of 4% that we found involved all deep infections, including late hematogenous infections; the 2% that led to revision was at the same level as in other reports. Thus, [@CIT0006] found a rate of 3%, [@CIT0017] found a rate of 3%, and [@CIT0022] reported 7%. The anterior incision used for total ankle replacement surgery is considered to indicate a high risk of healing complications. Other risk factors are smoking, peripheral vascular disease, and cardiovascular disease ([@CIT0022]) but [@CIT0017] only found inflammatory arthritis to be a statistically significant risk factor for major wound complications.

The surgical challenge in performing a total ankle replacement and the long learning curve is well known ([@CIT0001], [@CIT0005], [@CIT0009]), and in our earlier study we found that experience reduced the revision rate ([@CIT0009]). This study supports that finding, since the results have improved with time.

Bai et al. (2010) found that complications and secondary surgical procedures were higher in posttraumatic patients than in patients with primary osteoarthritis, but we found similar survival rates concerning different diagnoses ([Figure 2](#F2){ref-type="fig"}).

An obvious limitation of reports from national registries is the uncertainty of adequate reporting from different centers. We are personally acquainted with every surgeon who performs total ankle replacement in Sweden. Furthermore, we have compared data with information from hospital records, and in recent years also with data from the Nation Health Authority. The reporting rate can therefore be considered to be complete.

Another limitation of our study is the problem of bilateral cases, which were included in our survival analyses. 3 patients were revised bilaterally. However, [@CIT0018] reviewed the literature on the effect of including bilateral observations and found that all reports suggest a negligible effect on survival estimates.

It seems appropriate to inform presumptive patients that the probability of retaining an ankle arthroplasty of modern design for 10 years is about 80%. They should also be informed that when a total ankle replacement fails, there is the possibility of performing a successful ankle arthrodesis by various methods: intramedullary nailing through a femoral head autograft ([@CIT0021]), anterior plating ([@CIT0016], [@CIT0003]), or the use of an intramedullary nail through a trabecular metal implant ([@CIT0010]). Caution can no doubt be recommended with posttraumatic cases and with younger patients, especially younger women with osteoarthritis.
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